Australia's most trusted
source of pharma news
Thursday, 11 September 2025
Posted 9 September 2025 PM
The sale of ASX-listed Mayne Pharma to US-based Cosette Pharmaceuticals is getting dramatic, with both sides claiming incorrect information is being used against them.
Over the weekend South Australian Premier Peter Malinauskas said that he had lodged an objection to the $672 million deal announced in February, because Cosette had indicated it plans to close Mayne's Salisbury manufacturing site if the deal goes through, according to media reports.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.